Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Astrazeneca Plc ADR (AZN)

Astrazeneca Plc ADR (AZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 207,864,768
  • Shares Outstanding, K 3,100,608
  • Annual Sales, $ 45,811 M
  • Annual Income, $ 5,955 M
  • EBIT $ 9,201 M
  • EBITDA $ 14,588 M
  • 60-Month Beta 0.45
  • Price/Sales 4.58
  • Price/Cash Flow 12.53
  • Price/Book 5.14

Options Overview Details

View History
  • Implied Volatility 21.15% ( -1.97%)
  • Historical Volatility 30.91%
  • IV Percentile 45%
  • IV Rank 28.31%
  • IV High 34.77% on 10/31/24
  • IV Low 15.77% on 05/28/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 4,653
  • Volume Avg (30-Day) 20,247
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 163,970
  • Open Int (30-Day) 159,295

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.07
  • Number of Estimates 5
  • High Estimate 1.21
  • Low Estimate 1.01
  • Prior Year 0.73
  • Growth Rate Est. (year over year) +46.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
62.75 +8.96%
on 11/18/24
73.68 -7.21%
on 11/04/24
-3.05 (-4.27%)
since 11/01/24
3-Month
62.75 +8.96%
on 11/18/24
85.99 -20.49%
on 09/04/24
-17.35 (-20.24%)
since 09/03/24
52-Week
60.47 +13.06%
on 02/12/24
87.68 -22.02%
on 08/30/24
+3.58 (+5.53%)
since 12/01/23

Most Recent Stories

More News
The Zacks Analyst Blog Highlights Chevron, AstraZeneca and Arista Networks

For Immediate ReleaseChicago, IL – December 2, 2024 – Zacks.com announces the list of Stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

ANET : 413.30 (+0.78%)
CVX : 162.05 (-0.10%)
AZN : 68.47 (+2.13%)
Top Stock Reports for Chevron, AstraZeneca & Arista Networks

Friday, November 29, 2024The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron Corp....

ANET : 413.30 (+0.78%)
CVX : 162.05 (-0.10%)
AZN : 68.47 (+2.13%)
CME : 239.18 (+1.52%)
EQIX : 962.45 (-0.25%)
WDAY : 254.87 (+1.36%)
Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch

Here's why Eli Lilly, Pfizer, and AstraZeneca are biotech stocks worth considering, with strong pipelines and growth potential beyond vaccines.

AZN : 68.47 (+2.13%)
HIMS : 32.22 (+4.44%)
LLY : 813.50 (+1.71%)
PFE : 25.79 (-0.12%)
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View

This week Novartis NVS upgraded its mid-term sales growth guidance. The European Commission approved Pfizer’s PFE hemophilia drug Hympavzi (marstacimab). AstraZeneca’s AZN Tagrisso was recommended...

AZN : 68.47 (+2.13%)
JNJ : 153.63 (-0.76%)
LLY : 813.50 (+1.71%)
NVS : 104.90 (+0.10%)
PFE : 25.79 (-0.12%)
2 Vaccine Stocks to Buy on the Dip

Given the cutting-edge pipeline for these two vaccine companies, double-digit slumps in these stocks present a compelling entry point for investors.

AZN : 68.47 (+2.13%)
MRK : 102.41 (+1.79%)
LLY : 813.50 (+1.71%)
MRNA : 42.67 (-3.59%)
3 Growth Stocks Trading Near Their 52-Week Lows to Buy Right Now

There are plenty of growth stocks trading at obscenely high valuations right now. Part of the reason for that is the current enthusiasm for all things artificial intelligence (AI)-related. Some of those...

AZN : 68.47 (+2.13%)
DLTR : 72.95 (+0.19%)
UPS : 129.81 (-3.14%)
Vaccine Stocks Slide, Psychedelic Stocks Surge After RFK Jr. HHS Nomination

Markets sent a clear message Friday following President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to head the Department of Health and Human Services (HHS). Vaccine stocks took a nosedive,...

CMPS : 4.40 (-2.00%)
PSIL : 11.82 (-1.83%)
ATAI : 1.6650 (-1.48%)
AZN : 68.47 (+2.13%)
BVNRY : 8.7200 (-3.54%)
NVAX : 8.73 (-0.46%)
MRNA : 42.67 (-3.59%)
CYBN : 10.77 (+7.70%)
GSK : 35.01 (+2.04%)
PFE : 25.79 (-0.12%)
BNTX : 117.76 (+0.48%)
SNY : 48.04 (+0.17%)
Kennedy’s Nomination Raises Stakes for FDA and Big Pharma

Robert F. Kennedy Jr., recently named President-elect Donald Trump’s nominee for Health and Human Services Secretary, has pledged sweeping reforms at the U.S. Food and Drug Administration (FDA). Kennedy,...

AZN : 68.47 (+2.13%)
MRNA : 42.67 (-3.59%)
PFE : 25.79 (-0.12%)
Pharma Stock Roundup: AZN, BAYRY's Earnings, ABBV's Pipeline Setback

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY announcing their results. AbbVie’s ABBV schizophrenia candidate, added from a recent...

BAYRY : 5.0300 (-0.59%)
AZN : 68.47 (+2.13%)
JNJ : 153.63 (-0.76%)
MRK : 102.41 (+1.79%)
ABBV : 182.91 (+0.63%)
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?

AstraZeneca just released some encouraging data about its weight loss drug candidates.

AZN : 68.47 (+2.13%)
LLY : 813.50 (+1.71%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition...

See More

Key Turning Points

3rd Resistance Point 68.16
2nd Resistance Point 67.85
1st Resistance Point 67.44
Last Price 68.47
1st Support Level 66.73
2nd Support Level 66.42
3rd Support Level 66.01

See More

52-Week High 87.68
Fibonacci 61.8% 77.28
Fibonacci 50% 74.07
Fibonacci 38.2% 70.86
Last Price 68.47
52-Week Low 60.47

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar